- Home
- EHI vs IPHA Comparison
EHI vs IPHA Comparison
Compare EHI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EHI | IPHA |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.5M | 169.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | EHI | IPHA |
|---|---|---|
| Price | $6.54 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 44.5K | 23.5K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 11.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.00 | $1.63 |
| 52 Week High | $7.75 | $2.63 |
Technical Indicators
Market Signals| Indicator | EHI | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 45.46 |
| Support Level | $6.44 | $1.69 |
| Resistance Level | $6.53 | $1.80 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 79.99 | 20.00 |
Price Performance
Historical ComparisonAbout EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.